Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three manufacturers of insulin, expanding low-cost access to the diabetes drug. Novo Nordisk agreed to cap insulin prices for the next five years so that Minnesotans won’t have to pay any more than $35 for monthly prescriptions.